PURPOSE: Clinical data suggest that the estrogen receptor (ER) contributes to chemotherapeutic responsiveness. However, ER status alone is not consistently predictive. In this study, we used a microarray approach to find novel ER-related genes that predicted chemotherapy responses, with the hope of providing a robust multi-variable prediction method. METHODS: One hundred and ten patients with stages II and III breast cancer were included. They received four preoperative cycles of a weekly PCb (paclitaxel plus carboplatin) regimen. A total of 55 training cases were used for marker discovery and for identification of any ER-related genes that may have been associated with a chemotherapeutic response ("training cases"). The other 55 patients were available as an independent validation set ("validation cases") to test, using immunohistochemistry (IHC). RESULTS: In the training set, 20 significantly differentially expressed genes were identified. Among these 20 genes, TFF1, ESR1, GATA3 and TFF3 were found to be ER-related. Among 55 independent validation cases, univariate analysis indicated that clinical variables and ER-related genes were all significantly associated with pCR. It was shown that the pCR rate was as high as 80% when these five factors were all negative. In contrast, these five factors were all positive in seven of nine chemo-resistant patients. CONCLUSION: In conjunction with levels of ER-related genes, expression of ER protein may provide important predictive outcomes for responses to neoadjuvant chemotherapy and may allow for the identification of a subgroup of patients who could significantly benefit from chemotherapy (or who may be resistant to it).
PURPOSE: Clinical data suggest that the estrogen receptor (ER) contributes to chemotherapeutic responsiveness. However, ER status alone is not consistently predictive. In this study, we used a microarray approach to find novel ER-related genes that predicted chemotherapy responses, with the hope of providing a robust multi-variable prediction method. METHODS: One hundred and ten patients with stages II and III breast cancer were included. They received four preoperative cycles of a weekly PCb (paclitaxel plus carboplatin) regimen. A total of 55 training cases were used for marker discovery and for identification of any ER-related genes that may have been associated with a chemotherapeutic response ("training cases"). The other 55 patients were available as an independent validation set ("validation cases") to test, using immunohistochemistry (IHC). RESULTS: In the training set, 20 significantly differentially expressed genes were identified. Among these 20 genes, TFF1, ESR1, GATA3 and TFF3 were found to be ER-related. Among 55 independent validation cases, univariate analysis indicated that clinical variables and ER-related genes were all significantly associated with pCR. It was shown that the pCR rate was as high as 80% when these five factors were all negative. In contrast, these five factors were all positive in seven of nine chemo-resistant patients. CONCLUSION: In conjunction with levels of ER-related genes, expression of ER protein may provide important predictive outcomes for responses to neoadjuvant chemotherapy and may allow for the identification of a subgroup of patients who could significantly benefit from chemotherapy (or who may be resistant to it).
Authors: Siwei Wei; Lingyan Liu; Jian Zhang; Jeremiah Bowers; G A Nagana Gowda; Harald Seeger; Tanja Fehm; Hans J Neubauer; Ulrich Vogel; Susan E Clare; Daniel Raftery Journal: Mol Oncol Date: 2012-10-25 Impact factor: 6.603
Authors: Friederike Hoellen; Athina Kostara; Thomas Karn; Uwe Holtrich; Ahmed El-Balat; Mike Otto; Achim Rody; Lars C Hanker Journal: Mol Clin Oncol Date: 2016-08-17
Authors: J Xue; Y Chi; Y Chen; S Huang; X Ye; J Niu; W Wang; L M Pfeffer; Z-M Shao; Z-H Wu; J Wu Journal: Oncogene Date: 2015-04-13 Impact factor: 9.867
Authors: E P Bastos; H Brentani; C A B Pereira; A Polpo; L Lima; R D Puga; F S Pasini; C A B T Osorio; R A Roela; M I Achatz; A P Trapé; A M Gonzalez-Angulo; M M Brentani Journal: PLoS One Date: 2016-05-06 Impact factor: 3.240
Authors: Ji Soo Choi; Hyeon-Man Baek; Suhkmann Kim; Min Jung Kim; Ji Hyun Youk; Hee Jung Moon; Eun-Kyung Kim; Youn Ki Nam Journal: PLoS One Date: 2013-12-19 Impact factor: 3.240